ACPA-status | IgG-ACPA AU/ml | Total IgG mg/ml | Total IgA mg/ml | Total IgM mg/ml | anti-CCP2 IgG μg/ml | anti-CCP2 IgA μg/ml | anti-CCP2 IgM μg/ml | |
---|---|---|---|---|---|---|---|---|
RA1-serum | + | 195 | 6.2 | 1.6 | 0.4 | 6 | 0 | 0 |
RA2-serum | + | 1121 | 4 | 1.1 | 1.2 | 18.2 | 0 | 0 |
RA3-serum | + | 273 | 7.8 | 2.4 | 1.2 | 8.4 | 0 | 0.2 |
RA4-serum | + | 752 | 3.7 | 2.2 | 0.3 | 31.8 | 5.6 | 0.7 |
RA5-serum | + | 59 | 4.7 | 1.2 | 0.4 | 7.8 | 0 | 0 |
RA6-serum | + | 407 | 4.4 | 3 | 0.6 | 17.5 | 1.1 | 0.9 |
RA7-serum | + | 514 | 6 | 5.4 | 1.0 | 20.4 | 0.5 | 2.8 |
RA8-serum | + | 826 | 5.1 | 1.2 | 1.0 | 59.2 | 0.7 | 1.3 |
RA-P1-serum | + | 2957 | 3.9 | 1.5 | 0.8 | 46.7 | 5.4 | 85.2 |
RA-P2-serum | + | 3859 | 4.8 | 1.8 | 1.0 | 60.3 | 5.9 | 98.6 |
RA9-serum | − | <25 | 4.8 | 1.6 | 1.6 | 2.1 | 0 | 0.9 |
RA10-serum | − | <25 | 6.6 | 1.8 | 0.8 | 0.8 | 0 | 0 |
HC1-serum | − | <25 | 4.6 | 1.5 | 3.4 | 0 | 0 | 0 |
HC2-serum | − | <25 | 5.8 | 2 | 3.8 | 0.5 | 0 | 0.8 |
RA11-SF | + | 423 | 6.2 | 1.8 | 0.6 | 3.3 | 0.6 | 7.3 |
RA12-SF | + | 176 | 7.3 | 1.2 | 0.4 | 16.5 | 0.2 | 2.8 |
RA13-SF | + | 2929 | 10 | 1.6 | 0.3 | 103.2 | 1.1 | 9.6 |
RA-P1-SF | + | 1691 | 2.5 | 0.8 | 0.8 | 58.2 | 4.3 | 101.4 |
RA-P2-SF | + | 2710 | 2.7 | 0.9 | 0.7 | 54.2 | 4.4 | 88.8 |
RA14-SF | − | <25 | 2.2 | 0.6 | 0.4 | 0 | 0 | 0.5 |
OA1-SF | − | <25 | 0.8 | 0 | 0 | 0 | 0 | 0 |
IgG-ACPA (AU/ml), total IgG, total IgA and total IgM were measured in serum or synovial fluid before purification of ACPA. Purified ACPA was measured for the IgG, IgA, and IgM concentration (μg/ml). The paired samples (P1 and P2) were selected for their high IgM ACPA levels (∼5000 AU/ml).
ACPA, anticitrullinated protein antibody; Ig, immunoglobulin; SF, synovial fluid; RA, rheumatoid arthritis; OA, osteoarthritis; P, paired sample; HC, healthy control.